PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

When will genomic research translate into clinical care -- and at what cost?

New study applies quantitative modeling to genomics

2013-01-04
(Press-News.org) BOSTON – Genomic research is widely expected to transform medicine, but progress has been slower than expected. While critics argue that the genomics "promise" has been broken – and that money might be better spent elsewhere -- proponents say the deliberate pace underscores the complexity of the relationship between medicine and disease and, indeed, argues for more funding.

But thus far, these competing narratives have been based mostly on anecdotes. Ramy Arnaout, MD, DPhil, a founding member of the Genomic Medicine Initiative at Beth Israel Deaconess Medical Center (BIDMC), decided it was time to look at genomics from a new perspective. So he turned to quantitative modeling, a numerical forecasting approach used to predict everything from weather events to the outcomes of political elections, and an extremely useful way to both set expectations and assist in decision-making.

Arnaout and colleagues knew that drug-related adverse outcomes cost the health-care system upwards of $80 billion a year, and that many such cases should be avoidable by choosing and dosing drug prescriptions according to a person's genome. So they developed a quantitative model to estimate how much time and money would be required to use genomics, specifically pharmacogenomics, to cut these adverse outcomes in half. Their findings, currently published online in the journal Clinical Chemistry, provide one of the first examples of data-driven estimates being applied to genomic medicine and offer a template for the use of quantitative modeling in this field.

How do the numbers add up? After analyzing their model for a range of situations, the research team found that the cost can be expected to be less than $10 billion, spread out over approximately 20 years.

"If you look across medicine, you can see specific places here and there where genomics is really starting to change things, but it's been hard to know how it all adds up in the big picture," explains Arnaout, who is also an Assistant Professor of Pathology at Harvard Medical School (HMS) and Associate Director of Clinical Microbiology at BIDMC. "Quantitative modeling is a standard approach for forecasting and setting expectations in many fields as we all remember from the recent presidential election and from the hurricane season. Genomics is so important and is so often on the minds of our patients, students and staff, that it seemed like a good idea to use modeling to get some hard numbers on where we're headed."

The idea for the study originated nearly two years ago, while Arnaout (whose laboratory studies genomics) and Sukhatme, BIDMC's Chief Academic Officer, were attending a lecture, shortly after the 10-year anniversary of the sequencing of the genome. "Vikas asked me, 'So when is genomics really going to change medicine?'" remembers Arnaout. "I realized I didn't know. And that got me thinking."

Arnaout and Sukhatme, together with coauthors Thomas Buck, MD, and Paulvalery Roulette, MD, of BIDMC and HMS, decided to try and answer this question by applying forecasting methods to a big clinical problem – drug-related adverse outcomes. "We know that preventable causes of these adverse outcomes -- patients' non-adherence, interactions between multiple drugs, and medical error, for example -- account for only a fraction of the millions of adverse outcomes that patients experience each year," explains Arnaout. "This leaves a significant number that are currently considered non-preventable and are thought to be caused by genomic variation."

By way of example, Arnaout explains that 30 million Americans currently use the blood-thinning drug warfarin. But because, in some cases, patients' genomes contain variants that make the standard dose of warfarin too high for them, these individuals are likely to experience bleeding, an extremely dangerous side effect. In fact, researchers now estimate that three-quarters of the variability in warfarin dosing requirement is due to these genomic variants, and they have already identified a set of variants in six specific genes that explain two-thirds of the variability.

"This kind of progress suggested an interesting thought experiment," says Arnaout. "What if we took existing examples in which there appears to be a carefully vetted, clinically useful connection between a specific adverse outcome and a specific genetic variant, found out how much it cost and how long it took to discover, and applied that model to all drugs? How much would it cost and how long would it take to cut adverse outcomes by 25 percent? How about by half?"

As data for the model, the authors selected eight associations involving six prescription drugs (clopidogrel, warfarin, escitalopram, carbamazepine, the nicotine-replacement patch and abacavir) and one drug class, the statin class of anticholesterol drugs.

Using an approach called Monte Carlo modeling, the team ran simulations to forecast the research investment required to learn how to cut adverse outcomes by meaningful amounts, and how long that research work would be expected to take. For statistical confidence, they ran their simulations thousands of times and explored a wide range of assumptions. "The results were surprising," says Arnaout. "Before we did this work, I couldn't have told you whether it would take a million dollars or a trillion dollars or whether it would take five years or a hundred years. But now, we've got a basis for thinking that we're looking at single-digit billions of dollars and a couple of decades. That may sound like a lot or a little, depending on your point of view. But with these numbers, we can now have a more informed conversation about planning for the future of genomic medicine."

The most important determinant of the numbers is the extent to which the examples used in the model will turn out to be representative of drugs as a whole. "It's a broad set of drugs that were used, but we know how the genome can surprise us," says senior author Sukhatme. "For example, you won't be able to use genomics to cut adverse outcomes in half if genomics turns out to explain less than half of the adverse outcomes. But even in that case, we found that pharmacogenomics will be able to make a significant dent in adverse outcomes – cutting them by a quarter – for multi-billion-dollar investments."

Also surprising, say the authors, was the timing. "As a rule, the fruits of research come only after research dollars have already been spent," points out Arnaout. This means that, in this case, hundreds of millions of dollars will be spent for "pump-priming" long before the public can expect to see any meaningful clinical impact. "It's one thing to say, 'Be patient,' based on just faith," he adds. "It's another to be able to say so based on data and a model. We now have that. This enables the conversation to shift to which indicators of progress to look for, over the five or so years of pump-priming, to make sure we're on track."

Can we go faster? "If we could enroll an ethnically diverse set of patients who are taking each of the 40 or 50 most commonly prescribed drugs, get their blood samples, and keep track of the adverse outcomes that some of them are bound to experience, we should be able to move faster, for less money," adds Arnaout, who describes this idea as a "50,000 Pharmacogenomes Project," a pursuit along the lines of the 1,000 Genomes Project, the UK10K or the Veteran's Association Million Veteran Program.

"This model provides the start of a provocative conversation and illustrates the value of quantitative modeling in this very practical and publically relevant aspect of genomics," adds BIDMC Chief of Pathology Jeffrey Saffitz, MD, PhD. "Such models should help both decision makers and the public set expectations and priorities for translating genomic research into better patient care."

### Arnaout is funded through the Klarman Family Foundation.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and is currently ranked third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org. END



ELSE PRESS RELEASES FROM THIS DATE:

Rainfall, brain infection linked in sub-Saharan Africa

Rainfall, brain infection linked in sub-Saharan Africa
2013-01-04
UNIVERSITY PARK, Pa. -- The amount of rainfall affects the number of infant infections leading to hydrocephalus in Uganda, according to a team of researchers who are the first to demonstrate that these brain infections are linked to climate. Hydrocephalus -- literally "water on the brain" -- is characterized by the build-up of the fluid that is normally within and surrounding the brain, leading to brain swelling. The swelling will cause brain damage or death if not treated. Even if treated, there is only a one-third chance of a child maintaining a normal life after post-infectious ...

Researchers seek longer battery life for electric locomotive

Researchers seek longer battery life for electric locomotive
2013-01-04
UNIVERSITY PARK, Pa. -- Norfolk Southern Railway No. 999 is the first all-electric, battery-powered locomotive in the United States. But when one of the thousand lead-acid batteries that power it dies, the locomotive shuts down. To combat this problem, a team of Penn State researchers is developing more cost-effective ways to prolong battery life. The experimental locomotive's batteries, just like automotive batteries, are rechargeable until they eventually die. A leading cause of damage and death in lead-acid batteries is sulfation, a degradation of the battery caused ...

Outsourced radiologists perform better reading for fewer hospitals

2013-01-04
UNIVERSITY PARK, Pa. -- Experience working for a particular hospital matters when it comes to the performance of radiologists who work for outsourcing teleradiology companies, according to a team of researchers, whose finding could have important implications, given the growing use of telemedicine. "More than half of all hospitals now use teleradiology services," said Jonathan Clark, assistant professor of health policy and administration, Penn State. "Hospitals send their X-rays, CT scans, MRIs and other images to outsourcing companies who then forward the images to ...

Scripps physicians call for change in cancer tissue handling

2013-01-04
SAN DIEGO – Genetic sequencing technology is altering the way cancer is diagnosed and treated, but traditional specimen handling methods threaten to slow that progress. That's the message delivered this week in a column appearing in the Journal of the American Medical Association (JAMA) by Scripps Clinic physicians Eric Topol, Kelly Bethel and Laura Goetz. Dr. Topol is a cardiologist who serves as chief academic officer of Scripps Health and director of the Scripps Translational Science Institute (STSI), leading Scripps' genomic medicine research efforts. Dr. Bethel ...

Research update: Jumping droplets help heat transfer

2013-01-04
CAMBRIDGE, MA -- Many industrial plants depend on water vapor condensing on metal plates: In power plants, the resulting water is then returned to a boiler to be vaporized again; in desalination plants, it yields a supply of clean water. The efficiency of such plants depends crucially on how easily droplets of water can form on these metal plates, or condensers, and how easily they fall away, leaving room for more droplets to form. The key to improving the efficiency of such plants is to increase the condensers' heat-transfer coefficient — a measure of how readily heat ...

Your brain on Big Bird

Your brain on Big Bird
2013-01-04
Using brain scans of children and adults watching Sesame Street, cognitive scientists are learning how children's brains change as they develop intellectual abilities like reading and math. The novel use of brain imaging during everyday activities like watching TV, say the scientists, opens the door to studying other thought processes in naturalistic settings and may one day help to diagnose and treat learning disabilities. Scientists are just beginning to use brain imaging to understand how humans process thought during real-life experiences. For example, researchers ...

Study reveals new survival strategy for bacteria exposed to antibiotics

2013-01-04
Researchers have uncovered a new way that some bacteria survive when under siege by antibiotics. This survival mechanism is fundamentally different from other, known bacterial strategies. Understanding it may be useful for designing drugs that target hard-to-treat bacterial strains, such as drug-resistant tuberculosis, an increasingly urgent public health problem. The study is based on Mycobacterium smegmatis, a cousin of the microbe that causes TB, and its response to the TB drug isoniazid. The research, by Yuichi Wakamoto of the University of Tokyo and Neeraj Dhar ...

Steroids that only nature could make on a large scale -- Until now

Steroids that only nature could make on a large scale -- Until now
2013-01-04
LA JOLLA, CA – January 3, 2013 – Scientists at The Scripps Research Institute (TSRI) have achieved a feat in synthetic chemistry by inventing a scalable method to make complex natural compounds known as "polyhydroxylated steroids." These compounds, used in heart-failure medications and other drugs, have been notoriously problematic to synthesize in the laboratory. The researchers demonstrated the new strategy by synthesizing ouabagenin [wa-bah-jenn-in], a close chemical cousin of ouabain, which Somali tribes once used as a potent poison on the tips of their arrows but ...

Coral records suggest that recent El Nino activity rises above noisy background

Coral records suggest that recent El Nino activity rises above noisy background
2013-01-04
VIDEO: By studying a set of fossil corals that are as much as 7,000 years old, scientists have dramatically expanded the amount of information available on the El Nino-Southern Oscillation, a... Click here for more information. By examining a set of fossil corals that are as much as 7,000 years old, scientists have dramatically expanded the amount of information available on the El Nino-Southern Oscillation, a Pacific Ocean climate cycle that affects climate worldwide. The ...

Rethinking bacterial persistence

2013-01-04
It's often difficult to completely eliminate a bacterial infection with antibiotics; part of the population usually manages to survive. We've known about this phenomenon for quite some time, dating back nearly to the discovery of penicillin. For more than 50 years, scientists have believed that the resistant bacteria were individuals that had stopped growing and dividing. Up to now, in fact, it hasn't been possible to track the growth of cells before and after their exposure to antibiotics, which makes any analysis of the phenomenon quite imprecise. "Using microfluidics, ...

LAST 30 PRESS RELEASES:

Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[Press-News.org] When will genomic research translate into clinical care -- and at what cost?
New study applies quantitative modeling to genomics